Antimicrobial Resistance Mitigation

Antimicrobial Resistance Mitigation For Novel Anti-Infective Agents During the Preclinical Drug Development Stage

As sure as the sun will rise tomorrow, so will emergence of resistance to new anti-infective agents. It is as sure as the seasons. It is the force of evolution itself.

Tawanda Gumbo
MD

Antimicrobial Resistance Mitigation

Praedicare houses several of the infectious diseases physicians, public health experts, and mathematical modelers who pioneered the techniques, methods, and skills to allow the approaches described here to effect antimicrobial resistance emergence mitigation.

At Praedicare, we recognize that the emergence of antimicrobial resistance [AMR] to novel drugs is an integral part of the life cycle of that agent once approved for clinical use by drug regulating agencies, with dire global health consequences. Therefore, we developed a specific program to mitigate that, to predict that, and to diagnose that, even before drug gets to the clinic. We have developed a step-by-step approach, and the necessary standard operating procedures, to help biotech companies develop antimicrobials access this process. This includes antibacterial agents, antiviral agents, anti-parasitic agents, and antifungal agents. Out output includes optimal dosing strategies and identification of key companion drugs to mitigate Antimicrobial Resistance emergence, development of diagnostic kits to identify the resistance, and the solutions to apply when the resistance is eventually identified.

At Praedicare we also work with hospital antibiotic stewardship committees using mathematical models and simulations-based on hospital quarterly data to predict antibiotic resistance patterns in subsequent quarters, and patients’ demographics, organism isolate whole genome sequences, and human population genetics, to develop an antibiotic selection and dosing strategy specific to the health center. We can model and forecast the evolution of resistance in the future based on the past, using mathematics and wet lab tools. We give antibiotic stewardship committees tools to deal with Antimicrobial Resistance, and to foresee it.

Predicting Clinical Toxicity & Further Mechanisms of Effect

Dose-effect testing using human 3D organotypic organoids & predicted human Pharmacokinetics. In addition, we provide comparative data of signatures with Praedicare’s proprietary database of signatures of known drugs using AI.

Antimicrobial Resistance Mitigation

Praedicare houses several of the infectious diseases physicians, public health experts, and mathematical modelers who pioneered the techniques, methods, and skills to allow the approaches described here to effect antimicrobial resistance emergence mitigation.

At Praedicare, we recognize that the emergence of antimicrobial resistance [AMR] to novel drugs is an integral part of the life cycle of that agent once approved for clinical use by drug regulating agencies, with dire global health consequences. Therefore, we developed a specific program to mitigate that, to predict that, and to diagnose that, even before drug gets to the clinic. We have developed a step-by-step approach, and the necessary standard operating procedures, to help biotech companies develop antimicrobials access this process. This includes antibacterial agents, antiviral agents, anti-parasitic agents, and antifungal agents. Out output includes optimal dosing strategies and identification of key companion drugs to mitigate Antimicrobial Resistance emergence, development of diagnostic kits to identify the resistance, and the solutions to apply when the resistance is eventually identified.

At Praedicare we also work with hospital antibiotic stewardship committees using mathematical models and simulations-based on hospital quarterly data to predict antibiotic resistance patterns in subsequent quarters, and patients’ demographics, organism isolate whole genome sequences, and human population genetics, to develop an antibiotic selection and dosing strategy specific to the health center. We can model and forecast the evolution of resistance in the future based on the past, using mathematics and wet lab tools. We give antibiotic stewardship committees tools to deal with Antimicrobial Resistance, and to foresee it.

Predicting Clinical Toxicity & Further Mechanisms of Effect

Dose-effect testing using human 3D organotypic organoids & predicted human Pharmacokinetics. In addition, we provide comparative data of signatures with Praedicare’s proprietary database of signatures of known drugs using AI.

INTERESTED IN LEARNING MORE?

Contact Us Today

19

Number of Biopharma

Companies Worked With

51

Number of Projects

Worked On

INTERESTED IN LEARNING MORE?

Contact Us Today

21

56

Number of Biopharma

Companies Worked With

Number of Projects

Worked On